Literature DB >> 7721451

Effects of L-arginine infusion on renal hemodynamics in patients with mild essential hypertension.

Y Higashi1, T Oshima, R Ozono, M Watanabe, H Matsuura, G Kajiyama.   

Abstract

Previous studies have shown that endothelium-derived relaxing factor/nitric oxide plays an important role in the regulation of systemic and renal hemodynamics. The purpose of the present study was to determine whether endothelium-dependent renovascular relaxation was impaired in patients with mild essential hypertension who had normal renal plasma flow and glomerular filtration rate. We evaluated the effects of intravenous administration of L-arginine on blood pressure and renal hemodynamics in 13 patients with mild essential hypertension and 15 normotensive control subjects. L-Arginine infusion (500 mg/kg over 30 minutes) reduced mean blood pressure (from 82.5 +/- 2.5 to 76.3 +/- 2.6 mm Hg in hypertensive patients and from 106.1 +/- 3.0 to 97.5 +/- 2.9 mm Hg in control subjects; P < .001) and renovascular resistance (from 0.084 +/- 0.009 to 0.067 +/- 0.009 mm Hg.mL-1.min-1.[1.48 m2]-1 and from 0.105 +/- 0.010 to 0.093 +/- 0.011 mm Hg.mL-1.min-1.[1.48 m2]-1, respectively; P < .001). L-Arginine infusion increased renal plasma flow (from 602 +/- 36 to 698 +/- 40 mL.min-1.[1.48 m2]-1, P < .05) in normotensive subjects but not in hypertensive subjects, and glomerular filtration rate was unaffected in both groups. Although the L-arginine-induced reduction in mean blood pressure was similar in both groups, the decline in renovascular resistance was smaller in hypertensive subjects. The response of renal plasma flow was also smaller in hypertensive subjects. These findings suggest that dysfunction of the L-arginine-nitric oxide pathway exists in the renal circulation even in mild essential hypertension with normal renal plasma flow and glomerular filtration rate.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7721451     DOI: 10.1161/01.hyp.25.4.898

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  16 in total

1.  Notoginsenoside R1 reduces blood pressure in spontaneously hypertensive rats through a long non-coding RNA AK094457.

Authors:  Ying Yang; Peng Xi; Yuan Xie; Cuimei Zhao; Jiahong Xu; Jinfa Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Exogenous L-arginine does not affect angiotensin II-induced renal vasoconstriction in man.

Authors:  M Wolzt; A Ugurluoglu; L Schmetterer; G Dorner; G Zanaschka; C Mensik; H G Eichler
Journal:  Br J Clin Pharmacol       Date:  1998-01       Impact factor: 4.335

Review 3.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

4.  Upregulation of cyclooxygenase-2 expression in porcine macula densa with chronic nitric oxide synthase inhibition.

Authors:  M Kommareddy; R M McAllister; V K Ganjam; J R Turk; M Harold Laughlin
Journal:  Vet Pathol       Date:  2010-12-15       Impact factor: 2.221

Review 5.  Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension.

Authors:  Qiang Li; Ji-Youn Youn; Hua Cai
Journal:  J Hypertens       Date:  2015-06       Impact factor: 4.844

6.  Exogenous L-arginine ameliorates angiotensin II-induced hypertension and renal damage in rats.

Authors:  Niwanthi W Rajapakse; Carmen De Miguel; Satarupa Das; David L Mattson
Journal:  Hypertension       Date:  2008-11-03       Impact factor: 10.190

Review 7.  Endothelial nitric oxide (NO) and its pathophysiologic regulation.

Authors:  Anuran Chatterjee; Stephen M Black; John D Catravas
Journal:  Vascul Pharmacol       Date:  2008-07-20       Impact factor: 5.773

8.  Exogenous L-arginine attenuates the effects of angiotensin II on renal hemodynamics and the pressure natriuresis-diuresis relationship.

Authors:  Satarupa Das; David L Mattson
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-04       Impact factor: 2.557

9.  Role of quercetin and arginine in ameliorating nano zinc oxide-induced nephrotoxicity in rats.

Authors:  Laila M Faddah; Nayira A Abdel Baky; Nouf M Al-Rasheed; Nawal M Al-Rasheed; Amal J Fatani; Muhammad Atteya
Journal:  BMC Complement Altern Med       Date:  2012-05-02       Impact factor: 3.659

10.  Sex differences in renal responses to hyperglycemia, L-arginine, and L-NMMA in humans with uncomplicated type 1 diabetes.

Authors:  David Z I Cherney; James W Scholey; Etienne B Sochett
Journal:  Diabetes Care       Date:  2012-12-18       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.